ARAV Aravive Inc

Price (delayed)

$0.97

Market cap

$27.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.12

Enterprise value

-$34.51M

Aravive, Inc. is a clinical-stage oncology company developing transformative therapeutics designed to halt the progression of life-threatening diseases. Aravive is based in Houston, Texas and received a Product Development Award ...

Highlights
The company's revenue rose by 39% YoY and by 11% QoQ
ARAV's gross profit is up by 39% YoY and by 11% QoQ
The company's quick ratio has shrunk by 61% YoY
The company's net income has shrunk by 59% YoY and by 13% QoQ

Key stats

What are the main financial stats of ARAV
Market
Shares outstanding
28.83M
Market cap
$27.96M
Enterprise value
-$34.51M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.52
Price to sales (P/S)
2.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.17
Earnings
Revenue
$8.28M
EBIT
-$44.2M
EBITDA
-$43.25M
Free cash flow
-$35.05M
Per share
EPS
-$2.12
Free cash flow per share
-$1.66
Book value per share
$1.86
Revenue per share
$0.39
TBVPS
$3.5
Balance sheet
Total assets
$73.87M
Total liabilities
$34.67M
Debt
$5.79M
Equity
$39.2M
Working capital
$49.27M
Liquidity
Debt to equity
0.15
Current ratio
3.49
Quick ratio
3.45
Net debt/EBITDA
1.44
Margins
EBITDA margin
-522.4%
Gross margin
100%
Net margin
-534%
Operating margin
-575.5%
Efficiency
Return on assets
-58.2%
Return on equity
-88.5%
Return on invested capital
N/A
Return on capital employed
-81.7%
Return on sales
-534%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARAV stock price

How has the Aravive stock price performed over time
Intraday
1.2%
1 week
2.22%
1 month
-20.66%
1 year
-81.77%
YTD
-55.71%
QTD
-49.74%

Financial performance

How have Aravive's revenue and profit performed over time
Revenue
$8.28M
Gross profit
$8.28M
Operating income
-$47.64M
Net income
-$44.2M
Gross margin
100%
Net margin
-534%
The operating income has dropped by 67% year-on-year and by 17% since the previous quarter
The company's net income has shrunk by 59% YoY and by 13% QoQ
The company's revenue rose by 39% YoY and by 11% QoQ
ARAV's gross profit is up by 39% YoY and by 11% QoQ

Growth

What is Aravive's growth rate over time

Valuation

What is Aravive stock price valuation
P/E
N/A
P/B
0.52
P/S
2.48
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-4.17
The company's EPS fell by 28% YoY and by 9% QoQ
ARAV's P/B is 69% below its 5-year quarterly average of 1.7 and 63% below its last 4 quarters average of 1.4
The company's equity fell by 43% YoY and by 7% QoQ
The price to sales (P/S) is 81% less than the 5-year quarterly average of 12.7 and 67% less than the last 4 quarters average of 7.4
The company's revenue rose by 39% YoY and by 11% QoQ

Efficiency

How efficient is Aravive business performance
The ROE has shrunk by 80% YoY and by 30% QoQ
Aravive's ROA has plunged by 51% YoY and by 18% from the previous quarter
The company's return on sales fell by 14% YoY

Dividends

What is ARAV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARAV.

Financial health

How did Aravive financials performed over time
Aravive's total assets is 113% higher than its total liabilities
ARAV's total liabilities has surged by 87% year-on-year and by 36% since the previous quarter
Aravive's current ratio has shrunk by 61% YoY
The company's debt is 85% lower than its equity
The company's equity fell by 43% YoY and by 7% QoQ
The company's debt fell by 30% YoY and by 9% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.